NCT07147465 Performance Indicators and Impact on the Care Pathway of Sequencing on the SeqOIA and AURAGEN (Seqogen) Platforms for Oncology Patients
| NCT ID | NCT07147465 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Condition | Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,149 participants |
| Start Date | 2025-07-01 |
| Primary Completion | 2026-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,149 participants in total. It began in 2025-07-01 with a primary completion date of 2026-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
As part of the French Genomic Medicine Plan 2025 (FGM), the SeqOIA and AURAGEN platforms were selected to perform high-throughput genomic sequencing. The SONCO (Sequencing Oncology Cohort) project combines their medical and economic evaluations into a single national cohort. Its objective is to assess the impact of genomic sequencing on care pathways and treatment recommendations by collecting indicators related to quality, turnaround time, and patient information. Clinical data are gathered from molecular tumor board reports (via SPICE and HYGEN) and from hospital medical records. This cohort is intended to support public health decision-making and help anticipate the organization of future genomic platforms.
Eligibility Criteria
Inclusion Criteria: * Patients diagnosed with cancer and referred for high-throughput sequencing * Sequencing pre-indication validated: Patients for whom the pre-indication for sequencing the genome, exome, and RNA has been validated by the upstream RCP (Multidisciplinary Tumor Board) since January 1, 2021. Consent for data reuse: Patients who have agreed to the reuse of their medical and genomic data for research purposes and have not opposed this use. Exclusion Criteria: * Opposition to data reuse, unvalidated upstream RCP
Contact & Investigator
Isabelle DURAND-ZALESKI, Professor
PRINCIPAL INVESTIGATOR
Greater Paris University Hospitals
Frequently Asked Questions
Who can join the NCT07147465 clinical trial?
This trial is open to participants of all sexes, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07147465 currently recruiting?
Yes, NCT07147465 is actively recruiting participants. Visit ClinicalTrials.gov or contact Assistance Publique - Hôpitaux de Paris to inquire about joining.
Where is the NCT07147465 trial being conducted?
This trial is being conducted at Lyon, France, Paris, France, Paris, France.
Who is sponsoring the NCT07147465 clinical trial?
NCT07147465 is sponsored by Assistance Publique - Hôpitaux de Paris. The principal investigator is Isabelle DURAND-ZALESKI, Professor at Greater Paris University Hospitals. The trial plans to enroll 3,149 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.